Press releases

Sequana Medical announces 2018 Full Year Results and 2019 Outlook

Ghent, BELGIUM – 4 April 2019 – Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, today announces its business highlights and financial results for the year ended 31 December 2018, prepared...

Sequana Medical Notice of 2018 Full Year Results and 2019 Outlook

Ghent, BELGIUM – 28 March 2019 – Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, will announce its results for the full year ended 31 December 2018 and outlook for 2019...

Extraordinary General Shareholders’ Meeting to be held on 25 April 2019

Regulated Information Ghent, BELGIUM – 26 March 2019 (19:00 CET) – Sequana Medical NV [Euronext Brussels: SEQUA] (“Sequana Medical”, the “Company”) today invited the holders of securities issued by the Company to attend an extraordinary shareholders’ meeting before notary public on Thursday 25 April 2019. The agenda items of the extraordinary shareholders’ meeting relate to...

Transparency Notifications from Shareholders

Ghent, BELGIUM – 25 February 2019 – Sequana Medical NV (“Sequana Medical”, the “Company”), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today in accordance with article 14 of the Belgian Act of...

Disclosure of outstanding voting securities

Ghent, BELGIUM – 18 February 2019 – Sequana Medical NV – Euronext Brussels SEQUA (“Sequana Medical”, the “Company”), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today in accordance with article 15 of...

Sequana Medical establishes new corporate headquarters in Ghent, Belgium and raises €8.5 million from leading Belgian investors including Newton Biocapital, PMV and SFPI-FPIM as well as existing shareholders

Ghent, BELGIUM – October 15, 2018 – Sequana Medical NV (“Sequana Medical”, the “Company”), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today the opening of its new corporate headquarters in Ghent, Belgium,...

Sequana Medical reports positive data on use of the alfapump® in malignant ascites patients at the International Gynecologic Cancer Society

Zurich, SWITZERLAND – 17 September 2018 – Sequana Medical AG (“Sequana Medical”), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today positive findings from its Retrospective Malignant Ascites Study. The study retrospectively evaluated...

Sequana Medical announces presentation of pre-clinical proof of concept results of its Direct Sodium Removal (DSR) therapy for the management of volume overload in heart failure at the Annual Scientific Meeting of the Heart Failure Society of America (HFSA)

Zurich, SWITZERLAND – 17 September 2018 – Sequana Medical AG (“Sequana Medical”), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today positive findings from its Direct Sodium Removal (“DSR”) therapy proof of concept...

Sequana Medical Announces the Appointment of Kirsten Van Bockstaele as Chief Financial Officer

Zurich, SWITZERLAND – July 12, 2018 – Sequana Medical AG (“Sequana Medical”), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today the appointment of Kirsten Van Bockstaele as Chief Financial Officer, with immediate...

Sequana Medical announces inclusion of alfapump® in EASL Clinical Practice Guidelines and presentation of study demonstrating physical component of QOL is predictor of mortality in refractory ascites.

Zurich, SWITZERLAND – 16. May 2018 — Sequana Medical AG (“Sequana Medical”), a commercial stage medical device company and an innovator in the management of liver disease & malignant ascites, announces two important developments at the recent EASL (European Association for the Study of the Liver) International Liver Congress 2018. First, the inclusion of alfapump®...

Subscribe to our Press Releases

I agree to the Sequana Medical Privacy Policy

We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our
Privacy & Cookie Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close